In many ways the fortunes of Biospecifics Technologies Corporation (BSTC) are tied to those of Endo International (ENDP). Endo was previously in the middle of a war being fought over rising drug prices. It had been lumped in with price gougers like Bausch Health (BHC) and Turing Pharmaceuticals. Over the past year Endo has de-emphasized or shuttered pain-related drugs like Opana that became synonymous with price-gouging and/or the opioid crisis.
Endo has worked hard to put the opioid crisis behind it and find new catalysts to offset its sagging generics business. It may have turned the corner after reporting a solid financial performance in the second quarter of 2018.